title: Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
abstract: BACKGROUND
  Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second-line treatment of Helicobacter pylori infection. The effects were compared of 7-day low-dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients.
  
  
  METHODS
  Helicobacter pylori-positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10) or (ii) high-dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by (13)c-urea breath test 5 weeks after stopping medications. side-effects of treatments were documented.
  
  
  RESULTS
  A total of 120 patients were eligible for analysis. By intention-to-treat and per-protocol analysis, the eradication rates were 83% and 86% in the RAM-10 group and 75% and 76% in the RAM-20 group, respectively (P = 0.26 and P = 0.17). Both regimens were well-tolerated and compliance was >98% in both groups.
  
  
  CONCLUSIONS
  Low-dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well-tolerated therapy for the treatment of H. pylori infection in Chinese population.
authors.affiliation: Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam Road, Hong Kong.
authors.forename: Wai Man
authors.initials: WM
authors.lastname: Wong
authors.forename: Jiaqing
authors.initials: J
authors.lastname: Huang
authors.forename: Harry H X
authors.initials: HH
authors.lastname: Xia
authors.forename: Fiona M Y
authors.initials: FM
authors.lastname: Fung
authors.forename: Teresa S M
authors.initials: TS
authors.lastname: Tong
authors.forename: Kess L
authors.initials: KL
authors.lastname: Cheung
authors.forename: Vicky Y K
authors.initials: VY
authors.lastname: Ho
authors.forename: Kam Chuen
authors.initials: KC
authors.lastname: Lai
authors.forename: Chi Kuen
authors.initials: CK
authors.lastname: Chan
authors.forename: Annie O O
authors.initials: AO
authors.lastname: Chan
authors.forename: Chee-Kin
authors.initials: CK
authors.lastname: Hui
authors.forename: Shiu Kum
authors.initials: SK
authors.lastname: Lam
authors.forename: Benjamin C Y
authors.initials: BC
authors.lastname: Wong
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D016099:Endoscopy, Gastrointestinal; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015995:Prevalence; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D011706:Pyloric Antrum / Q000382:microbiology / Q000473:pathology; D064750:Rabeprazole; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D008795:Metronidazole; D064750:Rabeprazole; D000658:Amoxicillin; D006180:Proton-Translocating ATPases; D009853:Omeprazole